Search results
Results from the WOW.Com Content Network
Patiromer was generally well tolerated in studies. Side effects that occurred in more than 2% of patients included in clinical trials were mainly gastro-intestinal problems such as constipation, diarrhea, nausea, and flatulence, and also hypomagnesemia (low levels of magnesium in the blood) in 5% of patients, because patiromer binds magnesium in the gut as well.
Polystyrene sulfonates are a group of medications used to treat high blood potassium. [1] Effects generally take hours to days. [1] They are also used to remove potassium, calcium, and sodium from solutions in technical applications.
Potassium binders are medications that bind potassium ions in the gastrointestinal tract, thereby preventing its intestinal absorption. This category formerly consisted solely of polystyrene sulfonate, a polyanionic resin attached to a cation, administered either orally or by retention enema to patients who are at risk of developing hyperkalaemia (abnormal high serum potassium levels).
Sevelamer is used in the management of hyperphosphatemia in adult patients with stage 4 and 5 chronic kidney disease (CKD) on hemodialysis. Its efficacy at lowering phosphate levels is similar to that of calcium acetate, but without the accompanying risk of hypercalcemia and arterial calcification.
The potassium binder Veltassa is the most selling treatment in the nephrology segment. [ 19 ] CSL Vifor is a member of a number of trade associations that advocate on behalf of the pharmaceutical industry and for the policy positions commonly shared, this includes the European Federation of Pharmaceutical Industries and Associations (EFPIA). [ 20 ]
Other approved potassium binders in the United States include patiromer and sodium polystyrene sulfonate. [14] Hyperkalemia, particularly if severe, is a marker for an increased risk of death. [15] However, there is disagreement regarding whether a modestly elevated levels directly causes problems.
The most common side effects affecting more than 5% of patients are headache, upper respiratory tract infection, abdominal pain, diarrhea, rash, alanine aminotransferase increase, nasal congestion, blood creatine phosphokinase increase, aspartate aminotransferase increase, rhinorrhea, rhinitis, influenza, sinusitis, and blood bilirubin increase.
In 2002, the FDA issued a warning letter to Kraft that Velveeta was being sold with packaging that falsely described it as a "pasteurized process cheese spread", [11] The product listed milk protein concentrate (MPC) in its ingredients, which meant it no longer fit any of the FDA's cheese-related definitions.